Biologic Therapy of Leukemia Tapa dura - 2003

Primera línea

Excluding selected subsets of human leukemia, progress in the therapy of this group of disorders has been relatively modest since the late 1980s.

Descripción de contraportada

Exciting new "biologic" therapies for treating leukemia are appearing so rapidly that clinicians often find it difficult to make informed decisions about their use when making patient treatment decisions. In Biologic Therapy of Leukemia, distinguished physicians and medical researchers summarize and review all the available data concerning these cutting-edge biologic therapies so that practicing clinicians can make correct patient-care choices. Here the busy physician will find, in one convenient place, crucial information on the uses and limitations of the major biologic therapies for leukemia, the different biologic strategies for its treatment, the management of patients being treated with such biologic agents, and the current and future role of emerging biologic agents. Well-established therapies, such as interferon and all-trans-retinoic acid, are included so that their efficacy can be contrasted with such newer agents as imatinib mesylate and arsenic trioxide. P-glycoprotein inhibitors, interleukins, and the graft-vs-leukemia effect are also examined, along with approaches that reverse failure of apoptosis, alter genetic codes, and modulate immunologic mechanisms.
Authoritative and readily accessible, Biologic Therapy of Leukemia provides today's practicing oncologists with a comprehensive review of all currently available biologic approaches and agents, as well as the many different subtypes of leukemia, affording expert guidance in choosing optimal therapies for each patient.